| Revenue growth | 6.9% YoY revenue growth driven by non-GPL segment and new launches. |
|---|---|
| Margins | Record 33.6% EBITDA margin due to favorable product mix and efficiency. |
| Demand visibility | Stable demand in regulated markets; watchful of geopolitical uncertainty. |
| Management confidence | High; emphasizing resilience and successful transition under Nirma's ownership. |
Growth
FY26 revenue grew 6.9% to ₹2,552cr, led by 13% non-GPL growth; EBITDA margins expanded 366bps to 33.6%.
Outlook
Planned FY27 capex of ₹540cr for Solapur and Taloja R&D; targeting 2,690 KL capacity by FY28.
Risks
Dahej plant fire caused ₹20cr loss; global supply chain disruptions and solvent cost inflation remain persistent threats.
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,380.00
- Market cap
- ₹16,942 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.1×Sector 47.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
- Value
- ₹9.12 Cr
Alivus Life Sciences Business Update
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Annual Report
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.